Importantly, the authors showed that higher pre-diagnosis circulating OPG concentrations - assessed by an electrochemiluminescent assay - are associated with a greater risk of breast cancer-specific and overall mortality, especially in ER-positive breast cancer patients [137]. This evidence concerns the gene TNFRSF11B and breast cancer.